Literature DB >> 26025495

Management of neurogenic lower urinary tract dysfunction in multiple sclerosis patients.

Areeba Sadiq1, Benjamin M Brucker.   

Abstract

Multiple sclerosis (MS) can be a debilitating neurological condition that attributes significant morbidity to bladder dysfunction. Although many effective treatment options exist, symptomatic patients are often underdiagnosed and undertreated. The purpose of this article is to give an overview of the current literature including new screening tools to identify symptomatic patients and updates on treatment options including medications, botulinum toxin, and neuromodulation.

Entities:  

Mesh:

Substances:

Year:  2015        PMID: 26025495     DOI: 10.1007/s11934-015-0519-5

Source DB:  PubMed          Journal:  Curr Urol Rep        ISSN: 1527-2737            Impact factor:   3.092


  50 in total

1.  Percutaneous posterior tibial nerve stimulation as an effective treatment of refractory lower urinary tract symptoms in patients with multiple sclerosis: preliminary data from a multicentre, prospective, open label trial.

Authors:  C Gobbi; G A Digesu; V Khullar; S El Neil; G Caccia; C Zecca
Journal:  Mult Scler       Date:  2011-07-14       Impact factor: 6.312

2.  A novel therapy for nocturnal polyuria: a double-blind randomized trial of frusemide against placebo.

Authors:  J M Reynard; A Cannon; Q Yang; P Abrams
Journal:  Br J Urol       Date:  1998-02

3.  Under treatment of overactive bladder symptoms in patients with multiple sclerosis: an ancillary analysis of the NARCOMS Patient Registry.

Authors:  S T Mahajan; P B Patel; R A Marrie
Journal:  J Urol       Date:  2010-02-20       Impact factor: 7.450

Review 4.  Cannabis: pharmacology and toxicology in animals and humans.

Authors:  I B Adams; B R Martin
Journal:  Addiction       Date:  1996-11       Impact factor: 6.526

5.  Urologic status of 74 spinal cord injury patients from the 1976 Tangshan earthquake, and managed for over 20 years using the Credé maneuver.

Authors:  S M Chang; C L Hou; D Q Dong; H Zhang
Journal:  Spinal Cord       Date:  2000-09       Impact factor: 2.772

6.  OnabotulinumtoxinA improves urodynamic outcomes in patients with neurogenic detrusor overactivity.

Authors:  Eric Rovner; Roger Dmochowski; Christopher Chapple; Catherine Thompson; Wayne Lam; Cornelia Haag-Molkenteller
Journal:  Neurourol Urodyn       Date:  2013-02-06       Impact factor: 2.696

Review 7.  Timed voiding for the management of urinary incontinence in adults.

Authors:  J Ostaszkiewicz; L Johnston; B Roe
Journal:  Cochrane Database Syst Rev       Date:  2004

Review 8.  A UK consensus on the management of the bladder in multiple sclerosis.

Authors:  C J Fowler; J N Panicker; M Drake; C Harris; S C W Harrison; M Kirby; M Lucas; N Macleod; J Mangnall; A North; B Porter; S Reid; N Russell; K Watkiss; M Wells
Journal:  J Neurol Neurosurg Psychiatry       Date:  2009-05       Impact factor: 10.154

9.  Solifenacin in multiple sclerosis patients with overactive bladder: a prospective study.

Authors:  Farida van Rey; John Heesakkers
Journal:  Adv Urol       Date:  2011-05-05

10.  The conceptualization and development of a patient-reported neurogenic bladder symptom score.

Authors:  Blayne Welk; Sarah A Morrow; Wendy Madarasz; Patrick Potter; Keith Sequeira
Journal:  Res Rep Urol       Date:  2013-10-10
View more
  6 in total

1.  Nocturia in Patients With Multiple Sclerosis.

Authors:  Benoit Peyronnet; Lauren B Krupp; W Stuart Reynolds; Xavier Gamé; Gérard Amarenco; Jean-Nicolas Cornu; Lana Zhovtis Ryerson; Carrie Lyn Sammarco; Jonathan E Howard; Robert W Charlson; Roger R Dmochowski; Benjamin M Brucker
Journal:  Rev Urol       Date:  2019

Review 2.  Lower urinary tract dysfunction in common neurological diseases.

Authors:  Mohamad Moussa; Athanasios Papatsoris; Mohamed Abou Chakra; Yousef Fares; Athanasios Dellis
Journal:  Turk J Urol       Date:  2020-04-30

Review 3.  Secondary and tertiary treatments for multiple sclerosis patients with urinary symptoms.

Authors:  James M Tracey; John T Stoffel
Journal:  Investig Clin Urol       Date:  2016-10-24

Review 4.  The Management of Lower Urinary Tract Dysfunction in Multiple Sclerosis.

Authors:  Jure Tornic; Jalesh N Panicker
Journal:  Curr Neurol Neurosci Rep       Date:  2018-06-28       Impact factor: 5.081

5.  Effects of behavioural therapy versus interferential current on bladder dysfunction in multiple sclerosis patients; a randomised clinical study.

Authors:  Abdullah M Al-Shenqiti; Walaa M Ragab; Esraa H Rostum; Hatem A Emara; Osama A Khaled
Journal:  J Taibah Univ Med Sci       Date:  2021-09-01

6.  Intradetrusorial Botulinum Toxin in Patients with Multiple Sclerosis: A Neurophysiological Study.

Authors:  Antonella Conte; Antonella Giannantoni; Marilena Gubbiotti; Simona Pontecorvo; Enrico Millefiorini; Ada Francia; Massimo Porena; Alfredo Berardelli
Journal:  Toxins (Basel)       Date:  2015-08-26       Impact factor: 4.546

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.